Tekla Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Tekla Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$3.55M	Hold	504,528	–	–	0.14%	93
2023 Q1	$4.21M	Sell	504,528 -168,177	-25%	-$1.62M	0.16%	85
2022 Q4	$7.72M	Buy	672,705 +323,135	+92%	+$4.03M	0.29%	64
2022 Q3	$4.41M	Buy	349,570 +72,136	+26%	+$928K	0.18%	84
2022 Q2	$2.94M	Buy	277,434 +80,809	+41%	+$834K	0.12%	104
2022 Q1	$3.2M	Buy	+196,625	New	+$3.15M	0.11%	107
2018 Q1	–	Sell	-449,255	Closed	-$2.21M	–	189
2017 Q4	$2.21M	Buy	449,255 +126,000	+39%	+$610K	0.09%	122
2017 Q3	$1.69M	Buy	+323,255	New	+$1.66M	0.06%	126

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tekla Capital Management's BCRX Position: Q2 2023 in Review

Tekla Capital Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2023 at 504,528 shares worth $3.55M. The position accounts for 0.14% of the portfolio, ranked #93.

Tekla Capital Management first reported a position in BCRX in Q3 2017 and has held it in 8 quarters since. The position peaked at $7.72M in Q4 2022. 236 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

Tekla Capital Management held 504,528 shares of BioCryst Pharmaceuticals worth $3.55M as of Q2 2023.
Tekla Capital Management left its BioCryst Pharmaceuticals share count unchanged in Q2 2023.
BioCryst Pharmaceuticals made up 0.14% of Tekla Capital Management's portfolio in Q2 2023, its #93 holding.
Tekla Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2017 and has held it in 8 quarters since.
Tekla Capital Management's BioCryst Pharmaceuticals position peaked at $7.72M in Q4 2022.
236 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.